817204-35-6

Basic information

• Product Name: BenzaMide, N-[1,2-dihydro-1-(2-C-Methyl-β-D-arabinofuranosyl)-2-oxo-4-pyriMidinyl]-
• Synonyms: BenzaMide, N-[1,2-dihydro-1-(2-C-Methyl-β-D-arabinofuranosyl)-2-oxo-4-pyriMidinyl]-;N-(1-((2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide;N-[1-[(2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-2-oxopyrimidin-4-yl]benzamide
• CAS NO: 817204-35-6
• Molecular Formula: C₁₇H₁₉N₃O₆
• Molecular Weight: 361.34926
• Mol File: 817204-35-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BenzaMide, N-[1,2-dihydro-1-(2-C-Methyl-β-D-arabinofuranosyl)-2-oxo-4-pyriMidinyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzaMide, N-[1,2-dihydro-1-(2-C-Methyl-β-D-arabinofuranosyl)-2-oxo-4-pyriMidinyl]-(817204-35-6)
• EPA Substance Registry System: BenzaMide, N-[1,2-dihydro-1-(2-C-Methyl-β-D-arabinofuranosyl)-2-oxo-4-pyriMidinyl]-(817204-35-6)

Safety Data

• Hazardous Substances Data: 817204-35-6(Hazardous Substances Data)

Upstream product

• 917-54-4 methyllithium 
• 119411-03-9 N-[2-Oxo-1-((2R,3aR,9aR)-5,5,7,7-tetraisopropyl-3-oxo-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl)-1,2-dihydro-pyrimidin-4-yl]-benzamide 
• 65-46-3 CYTIDINE 
• 69304-43-4 1-[3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-β-D-ribofuranosyl]-N⁴-benzoylcytosine 
• 13089-48-0 N₄-benzoylcytidine 
• 93-97-0 benzoic acid anhydride 
• 817204-34-5 N⁴-benzoyl-1-[2-C-methyl-3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-arabinofuranosyl]cytosine 

Downstream Products

• 817204-32-3 (2R,3R,4R,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-((benzoyloxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate 
• 1192577-71-1 C₃₈H₃₇N₃O₈ 
• 1192577-81-3 C₃₃H₃₇N₃O₆Si 
• 863329-62-8 N⁴-benzoyl-1-(2-C-methyl-3,5-di-O-benzoyl-β-D-arabinofuranosyl)cytosine 

Relevant articles and documents

Method for synthesizing Sofosbuvir key intermediate

The invention provides a method for synthesizing a Sofosbuvir key intermediate. The method comprises the steps that alcohols and raw material compounds are added to a microwave reactor; the temperature of a system is gradually increased to a first tempera

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

Design, synthesis, and antiviral activity of 2′-deoxy-2′- fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication

The pyrimidine nucleoside beta-D-2′-deoxy-2′-fluoro-2′-C- methylcytidine (1) was designed as a hepatitis C virus RNA-dependent RNA polymerase (HCV RdRp) inhibitor. The title compound was obtained by a DAST fluorination of N4-benzoyl-1-(2-methyl-3,5-di-O-benzoyl-β-D- arabinofuranosyl]cytosine (6) to provide N4-benzoyl-1-[2-fluoro-2- methyl-3,5-di-O-benzoyl-β-D-ribofuranosyl]cytosine (7a). The protected 2′-C-methylcytidine (7c) was obtained as a byproduct from the DAST fluorination and allowed for the preparation of two biologically active compounds from a common precursor. Compound 1 and 2′-C-methylcytidine were assayed in a subgenomic HCV replicon assay system and found to be potent and selective inhibitors of HCV replication. Compound 1 shows increased inhibitory activity in the HCV replicon assay compared to 2′-C-methylcytidine and low cellular toxicity.